Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Revolution Medicines, Inc. (RVMD) had Return on Tangible Equity of -27.35% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-600.09M |
|
-- |
|
-- |
|
$689.52M |
|
$-689.52M |
|
$88.68M |
|
$-600.85M |
|
$-600.85M |
|
$-600.09M |
|
$-600.09M |
|
$-600.09M |
|
$-600.09M |
|
$-689.52M |
|
$-722.26M |
|
167.74M |
|
167.74M |
|
$-3.58 |
|
$-3.58 |
|
| Balance Sheet Financials | |
$2.33B |
|
$24.29M |
|
$230.67M |
|
$2.56B |
|
$163.91M |
|
-- |
|
$129.18M |
|
$293.10M |
|
$2.27B |
|
$2.19B |
|
$2.27B |
|
185.90M |
|
| Cash Flow Statement Financials | |
$-557.44M |
|
$-554.39M |
|
$959.41M |
|
$699.18M |
|
$546.76M |
|
$-152.42M |
|
$79.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-567.74M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-26.49% |
|
|
Return on Tangible Equity |
-27.35% |
-23.46% |
|
-26.49% |
|
$12.19 |
|
$-3.38 |
|
$-3.32 |
|